|
|
Blood, Vol. 113, Issue 15, 3428-3434, April 9, 2009
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party
Blood Castagnetti et al.
113: 3428
Supplemental materials for: Castagnetti et al
The following members of the “GIMEMA Working Party on CML” actively participated in this study:
Levis A and Pini M (Alessandria)
Bigazzi C (Ascoli Piceno)
Liso V (Bari)
Bassan R and Intermesoli T (Bergamo)
Marzocchi G (Bologna)
Capucci A and Rossi G (Brescia)
Girasoli M (Brindisi)
Giustolisi R (Catania)
Levato L and Peta A (Catanzaro)
Musolino C (Messina)
Luciano L and Rotoli B (Napoli)
Cilloni D and Fava C (Orbassano)
Semenzato G (Padova)
Musso M and Porretto F (Palermo)
Barulli S and Visani G (Pesaro)
Di Lorenzo R and Fioritoni G (Pescara)
Trabacchi E and Vallisa D (Piacenza)
Leone G and Sica S (Roma)
Abruzzese E and De Fabritiis P (Roma)
Foà R (Roma)
Petti MC (Roma)
Bocchia M and Lauria F (Siena)
Gherlinzoni F (Treviso)
Gallo E and Pregno P (Torino).
|
|
